PLEASE NOTE THAT SUBSEQUENT UTILIZATION OF MATERIAL PRESENTED DURING THE MEETING (SLIDES, TEXT, AND NARRATIVE) WITHOUT EXPRESS PERMISSION FROM THE AUTHOR IS NOT PERMITTED AND WILL BE CONSIDERED A COPYRIGHT VIOLATION. DELEGATES MUST REQUEST SPECIFIC PERMISSION FROM FACULTY MEMBERS IF THEY WISH TO REPRODUCE THEIR SLIDES FOR ANY PURPOSE.

---

Advocacy

1. Whitaker Platform Presentations
   
   • Welcome and Introduction ¦ Michael Racke, MD
   • A Model for Examining Novel Mechanisms of Neurodegeneration in an Animal Model of Multiple Sclerosis ¦ Cole Libner, BSc
   • Does 4 Weeks of Cognitive Rehabilitation Improve Processing Speed and Working Memory in MS? Results of Mindfulness Training Vs. Adaptive Computerized Training ¦ Heena Manglani, MA
   • Dysfunctional RNA Binding Protein Biology as Contributors to the Pathogenesis of Autoimmune Disease of the Central Nervous System ¦ Hannah Salapa, BS
   • Interferon Signature and Regulation in Progressive Multiple Sclerosis: Effects of Sc IFN-Beta-1a ¦ Xuan Feng, PhD
   • Q&A, Closing ¦ Michael Racke, MD
2. Access to Care
   • Practice Management ¦ Edward J. Fox, MD, PhD
   • Quality Measures and Outcomes ¦ Sarah Benish, MD
   • Debate: Community-based Centers vs. Hospital-based Centers ¦ Edward J. Fox, MD, PhD; John Corboy, MD
   • Q&A ¦ Panel

Comprehensive Care

1. Essential Topics in Caring for Persons with Progressive MS 
   • Managing Difficult Conversations ¦ Marijean Buhse, PhD, MP-C, MSCN
   • Applying Primary Palliative Care to Those with Advanced MS ¦ Rachael Stacom, MS, ANP-BC, MSCN
   • Empowering Persons with MS: Planning for Future Needs ¦ Patti Nelson Reade, RN, Esq. CELA
   • Panel Discussion 
2. Caring for Women Across the Reproductive Lifespan
   • Welcome and Overview ¦ Riley Bove, MD
   • Counseling Women about Contraception and the Menstrual Cycle ¦  Riley Bove, MD
   • Pregnancy and MS: Safely Navigating Childbearing, from Pre-pregnancy Planning to the Post-partum Period ¦  Maria Houtchens, MD, MMsci
   • Menopause: A Time of Changes and an Opportunity to Re-evaluate Comprehensive Wellness and Care ¦ Riley Bove, MD
   • Healthy Aging Beyond the Menopause: Tackling “Below the Belt” Function and Other Aspects of Wellness ¦ Tamara Kaplan, MD
3. An MS Health Professional’s Guide to Cannabis Allen C. Bowling, MD, PhD
   • History, Botany, Pharmacology
   • Efficacy and Safety
   • Drug Interactions and Special Considerations
   • The Critical Role of MS Health Professionals
4. Fundamentals of Multiple Sclerosis Care 2019: Identifying the Disease and Managing the Course (Part 1)
   • History of Multiple Sclerosis ¦ Randall T. Schapiro, MD, FAAN
   • The Natural History of MS (Epidemiology, Immunology, Pathophysiology, Phenotypes) ¦ Bruce Cohen, MD
   • Making the Diagnosis: Disease Mimics, Use of Paraclinical Tools ¦ Derrick Robertson, MD
   • Primary Progressive MS: Diagnosis, Clinical Course, and Long-term Management ¦ Patricia K. Coyle, MD
5. Fundamentals of Multiple Sclerosis Care 2019: Identifying the Disease and Managing the Course (Part 2)
   • RRMS: Current Treatment Options, Considerations in Choosing Treatment, Acute Relapse Management ¦ John Rinker, MD
   • Identifying and Managing Mood Disorders in MS ¦ Anthony Feinstein, MD, PhD
   • Women’s Issues in MS: Pregnancy, Menopause, Sexual Function ¦ Mitzi Joi Williams, MD
   • Integrative Medicine in the Comprehensive Care Model of MS ¦ Megan Weigel, DNP, ARNP-C, MSCN
6. Multidisciplinary Management of Chronic Pain in MS
   • Introduction to Multidisciplinary Management of Chronic Pain in MS ¦ Kevin Alschuler, PhD
   • Management of the MS Patient with Chronic Pain ¦ Brett R. Stacey, MD
   • Is There a Role for Opioids in MS Pain Management? A Case-Based Discussion ¦ Pamela Stitzlein Davies, MS, ARNP, FAANP
   • Physical Activity and Chronic Pain in MS ¦ Robert W. Motl, PhD
   • Cognitive Behavioral Interventions for Chronic Pain ¦ Dawn M. Ehde, PhD
   • Q&A ¦ Panel
7. The Importance of Community Based Programs to Enhance Comprehensive MS Care
   • Welcome and Introduction of Speakers ¦ Brian Hutchinson, PT, MSCS
   • Community-Based Wellness Models for Chronic Disease ¦ Brian Hutchinson, PT, MSCS
   • Building MS Communities, Expanding the Continuum of Care ¦ James Bowen, MD
   • A Community Based Yoga Program for People with MS: The Power of Connection ¦ Megan Weigel, DNP, ARNP-c, MSCN
   • The Multiple Sclerosis Achievement Center: A Day Program Model for People with MS ¦ Brian Hutchinson, PT, MSCS
8. Palliative Care in MS
   • Introduction ¦ Sarah Morrow, MD, MS, FRCPC
   • Description of the Consensus Conference-November 2018 ¦ Lori Mayer, DNP, MSN, RN, MSCN
   • Models of Palliative Care ¦ Rachel Stacom, MS, ANP-BC, MSCN
   • Clinical Experience Using the Palliative Care Model ¦ Benzi Kluger, MD, MS, FAAN
   • Case Studies with Learner Participation ¦ Panel
9. Update on Pediatric MS and Related Disorders
   • Overview: Changing Landscape in MS and Neuroinflammatory Disorders in Youth ¦ Giulia Longoni, MD
   • Do Lifestyle and Environment Make a Difference in Pediatric MS? ¦ Ann Yeh, MD
   • Therapies for Pediatric MS ¦ Jennifer Graves, MD, PhD, MAS
   • Transitional Issues in Youth with MS ¦ Jennifer Boyd, RN, MHSc, MSCN
10. Integrative Medicine: An Essential But Neglected Component of Comprehensive MS Care
    • Introduction, Relevance to Comprehensive Care, Science and Clinical Application, Research Update ¦ Allen C. Bowling, MD, PhD
    • Calorie-Restriction and Other Dietary Modification Strategies for MS Course ¦ Kathryn Fitzgerald, ScD, ScM
    • Constraint-Induced Movement Therapy ¦ Victor Mark, MD
    • Can High Intensity Training in MS Further Optimize Exercise Therapy Outcome? ¦ Charly Keytsman, PhD
11. Fundamentals of Multiple Sclerosis Care 2019 (Part 3)
    • Multidisciplinary Approach to Symptom Management ¦ Beverly Layton, RN, BSN, CCRC, MSCN
    • Pearls from Advanced Practice: Disease Modifying Therapies ¦ Marie Moore, MSN, FNP, MSCN
    • Emerging Role of Pharmacists in MS Centers ¦ Brittany Denson, PharmD
    • Current Options in Comprehensive Fatigue Management ¦ Patricia Pagnotta, ANP-C, MSCN
    • Symptoms Below the Belt: Strategies in the Management of Elimination and Sexual Dysfunction ¦ Marie Namey, APRN, MSN, MSCN
12. Mental Health Care Delivery Models for Patients with MS
    • The Current Landscape: Individuals with MS Need Better Access to Mental Health Services ¦ Sarah Minden, MD
    • Collaborative Care Model in Mental Health: Description, Components, and Review of its Evidence ¦ Jane Erb, MD
    • The Neurologist Perspective – Mental Health Needs of MS Patients and Role of the Neurologist ¦ Maria K. Houtchens, MD, MMsci
    • Q&A
    • Can the Collaborative Care Model Address the Mental Health Needs of Individuals with MS? Challenges and Opportunities ¦ Laura T. Safar, MD
    • The Social Worker Perspective – Care Management for MS Patients: Current Models and Future Developments ¦ Elizabeth Misasi, LICSW
    • Panel Discussion – Professional Adaptation and Role Changes in New Models ¦ Panel
    • Q&A ¦ Panel
13. Platform Presentations: Disease Assessment and Management
    • DXA01 Inroads: A Phase 3 Study to Assess the Efficacy and Safety of ADS-5102 (Amantadine) Extended Release Capsules in Multiple Sclerosis (MS) Patients with Walking Impairment ¦ Michelle Cameron, MD, PT, MCR
    • DXA02 Sleep Quality and Physical Activity in Youth with Multiple Sclerosis ¦ Stephanie Grover, MSc, CCRP
    • DXA03 Relevance of Timing of Mog Serum Testing: Does Positivity Always Signal Recurrence? ¦ Giulia Longoni, MD
    • DXA04 Impact of Cognitive Behavioral Therapy for Insomnia or Brief Sleep Education on Insomnia Symptoms, Fatigue, Depression, and Anxiety in Individuals with Multiple Sclerosis ¦ Stacy Coffyn, SPT
    • DXA05 Physical Activity, Sedentary Behavior, and Sleep Quality in Adults with Multiple Sclerosis across the Lifespan ¦ Katie Cederberg, MS
    • DXA06 The Economic Impact of Multiple Sclerosis: A Preliminary Look at the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) (on behalf of the NARCRMS HEOR Advisory Group) ¦ Kottil Rammohan, MD
14. Leveraging Multidisciplinary Care to Enhance Wellness in Individuals with MS
    • Leveraging Multidisciplinary Care to Enhance Wellness in Individuals with MS ¦ Gloria von Geldern, MD
    • Encouraging Wellness Behaviors and Integrating Wellness into Neurologic Care ¦ Annette Wundes, MD
    • Guiding Patients through the Complex World of MS Care ¦ Debra Cramer, RN
    • Physiatry and Rehabilitation Therapy Interventions to Promote Wellness ¦ Gloria Hou, MD
    • Promoting Wellness through Education, Employment, and Volunteering ¦ Joe Stuckey, MS, CRC
    • Promoting Wellness Behaviors through Health Behavior Change Interventions ¦ Samantha Artherholt, PhD
15. Treatment Adherence in MS: Identifying Suboptimal Adherence and Strategies for Improving Appointment Attendance and Medication Self-Management
    • Introduction ¦ Jodie K. Haselkorn, MD, MPH
    • Using Clinical Data to Build Predictive and Explanatory Models of Treatment Adherence ¦ Elizabeth S. Gromisch, PhD
    • Psychological Considerations in Suboptimal DMT Adherence ¦ Aaron Turner, PhD, ABPP
    • Using Motivational Interviewing and Telehealth to Improve Adherence ¦ Aaron Turner, PhD, ABPP; Alicia Sloan, MPH, MSW
    • Implementing Strategies into a Clinical Setting ¦ Panel
16. Sex and MS: How to Help Patients with MS Who Experience Sexual DysfunctionKimberly Castelo, MS, LMFT, CST

Disease Management

1. Psychopharmacology and MS: Review and Update for Clinicians
   
   • Psychopharmacology Overview: Classification, Indications, Mechanism of Action, and Common Adverse Effects of Psychopharmacological Agents ¦ Jane Erb, MD
   • Use of Psychotropics in MS: Antidepressants, Antianxiety Agents, Mood Stabilizers, Antipsychotics, Cognitive Enhancers, and Cannabis  ¦ Laura Safar, MD
   • Psychotropics Algorithm Selection Based on Clinical Scenario – Clinical Vignettes Discussion with Audience Participation  ¦ Panel
2. Presidential Lecture: Use and Abuse of the McDonald Criteria in MS DiagnosisFred D. Lublin, MD
3. Fundamentals of Multiple Sclerosis Care 2019: Identifying the Disease and Managing the Course (Part 1)
   • History of Multiple Sclerosis ¦ Randall T. Schapiro, MD, FAAN
   • The Natural History of MS (Epidemiology, Immunology, Pathophysiology, Phenotypes) ¦ Bruce Cohen, MD
   • Making the Diagnosis: Disease Mimics, Use of Paraclinical Tools ¦ Derrick Robertson, MD
   • Primary Progressive MS: Diagnosis, Clinical Course, and Long-term Management ¦ Patricia K. Coyle, MD
4. Fundamentals of Multiple Sclerosis Care 2019: Identifying the Disease and Managing the Course (Part 2)
   • RRMS: Current Treatment Options, Considerations in Choosing Treatment, Acute Relapse Management ¦ John Rinker, MD
   • Identifying and Managing Mood Disorders in MS ¦ Anthony Feinstein, MD, PhD
   • Women’s Issues in MS: Pregnancy, Menopause, Sexual Function ¦ Mitzi Joi Williams, MD
   • Integrative Medicine in the Comprehensive Care Model of MS ¦ Megan Weigel, DNP, ARNP-C, MSCN
5. Update on Pediatric MS and Related Disorders
   • Overview: Changing Landscape in MS and Neuroinflammatory Disorders in Youth ¦ Giulia Longoni, MD
   • Do Lifestyle and Environment Make a Difference in Pediatric MS? ¦ Ann Yeh, MD
   • Therapies for Pediatric MS ¦ Jennifer Graves, MD, PhD, MAS
   • Transitional Issues in Youth with MS ¦ Jennifer Boyd, RN, MHSc, MSCN
6. Practical Considerations in Relapse Management and Disease Modifying Therapy (DMT) Decision MakingBryan Walker, MHS, PA-C, MSCS; Stephanie Agrella, PhDc, MSN, RN, ANP-BC, MSCN
7. Basic Immunology for the Non-immunologist
   • How Does the Immune System Protect Us? ¦ Lisa Fox, PA
   • What Causes CNS Inflammation in MS? ¦ Scott D. Newsome, DO, MSCN, FAAN
   • How Do the Current DMTs Affect the Altered Immune Response in MS? ¦ Scott D. Newsome, DO, MSCN, FAAN
8. Advanced Immunology for the Non-immunologist
   • The Innate Immune System: An Emerging Target in MS ¦ Michael Kornberg, MD, PhD
   • The Innate Immune System: Effect of MS Disease Modifying Therapies ¦ Robert J. Fox, MD
   • Q&A
9. Platform Presentations: Disease Modifying Therapy
   • DXM01: Efficacy and Safety of Alemtuzumab in Patients of African Descent in CARE-MS I and II: 8-Year Follow-up (TOPAZ Study) ¦ Annette Okai, MD
   • DXM02: Treatment Patterns of Disease-Modifying Therapy Among Pediatric Patients with Multiple Sclerosis in the United States ¦ Chinmay Deshpande, PhD
   • DXM03: Changes in the Immune Cell Profile, Clinical and Safety Outcomes in Fingolimod-Treated Patients with Relapsing Multiple Sclerosis: Interim Results of the FLUENT Study ¦ Yang Mao-Draayer, MD, PhD
   • DXM04: Real-World Efficacy of Delayed-Release Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 24-Month Interim Results from ESTEEM ¦ Mitzi Joi Williams, MD
   • DXM05: The Effects of Cladribine Tablets on Reduction in MRI Lesions Are Consistent across Subgroups in the ORACLE-MS ¦ Study Thomas Leist, MD
   • DXM06: Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib (M2951) in Patients with Relapsing MS over 48 Weeks: A Phase II Study ¦ Jerry Wolinsky, MD (This speaker has opted not to publish this presentation.)
10. Platform Presentations: Disease Assessment and Management
    • DXA01 Inroads: A Phase 3 Study to Assess the Efficacy and Safety of ADS-5102 (Amantadine) Extended Release Capsules in Multiple Sclerosis (MS) Patients with Walking Impairment ¦ Michelle Cameron, MD, PT, MCR
    • DXA02 Sleep Quality and Physical Activity in Youth with Multiple Sclerosis ¦ Stephanie Grover, MSc, CCRP
    • DXA03 Relevance of Timing of Mog Serum Testing: Does Positivity Always Signal Recurrence? ¦ Giulia Longoni, MD
    • DXA04 Impact of Cognitive Behavioral Therapy for Insomnia or Brief Sleep Education on Insomnia Symptoms, Fatigue, Depression, and Anxiety in Individuals with Multiple Sclerosis ¦ Stacy Coffyn, SPT
    • DXA05 Physical Activity, Sedentary Behavior, and Sleep Quality in Adults with Multiple Sclerosis across the Lifespan ¦ Katie Cederberg, MS
    • DXA06 The Economic Impact of Multiple Sclerosis: A Preliminary Look at the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) (on behalf of the NARCRMS HEOR Advisory Group) ¦ Kottil Rammohan, MD
11. Beyond the PI: Drug-Drug Interactions (DDIs), Monitoring and Management
    • Precision Medicine and Applied Pharmacology for Anti-Depressants, Anti-Psychotics to Assist in Drug Selection and Monitoring to Avert Comorbidities in Patients with MS ¦ Rebecca Barnhart, PharmD, BCPP
    • Anatomy of Pharmacokinetic/ Pharmacodynamic Drug Interaction Implications ¦ Felecia Hart, PharmD, MSCS

Neuroscience / Environmental Factors

1. John F. Kurtzke Memorial Lecture: A Novel Subtype of Multiple SclerosisBruce D. Trapp, PhD
2. Whitaker Platform Presentations
   
   • Welcome and Introduction ¦ Michael Racke, MD
   • A Model for Examining Novel Mechanisms of Neurodegeneration in an Animal Model of Multiple Sclerosis ¦ Cole Libner, BSc
   • Does 4 Weeks of Cognitive Rehabilitation Improve Processing Speed and Working Memory in MS? Results of Mindfulness Training Vs. Adaptive Computerized Training ¦ Heena Manglani, MA
   • Dysfunctional RNA Binding Protein Biology ss Contributors to the Pathogenesis of Autoimmune Disease of the Central Nervous System ¦ Hannah Salapa, BS
   • Interferon Signature and Regulation in Progressive Multiple Sclerosis: Effects of Sc IFN-Beta-1a ¦ Xuan Feng, PhD
   • Q&A, Closing ¦ Michael Racke, MD
3. Mechanisms of Disease Pathogenesis in MS
   • Control of Immunopathology in CNS Autoimmunity ¦ Thomas Korn, MD, PhD
   • Regulation of Autoimmune CNS Disease by IL-17 ¦ Rachel R. Caspi, PhD
   • Environmental Regulation of Astrocyte Pathogenic Activities ¦ Francisco J. Quintana, PhD
   • MS: An Immune Miscommunication Disease? ¦ Burkhard Becher, PhD
   • Distinct Roles for CD8 T Lymphocytes in Central Nervous System Autoimmunity ¦ Joan Goverman, PhD
   • How Do B Cell Directed Therapies Impact MS? ¦ Jennifer Gommerman, PhD
   • How IL-1 Regulates CNS Inflammation ¦ Ari Waisman, PhD
4. Presidential Lecture: Use and Abuse of the McDonald Criteria in MS DiagnosisFred D. Lublin, MD
5. Understanding the Mechanism of Action of B-cell Depleting Drugs: What Does that Reveal about the Role of B-cells in MS?
   • Introduction ¦ Gregory Wu, PhD
   • The Role of B Cell Antigen Presentation in EAE and MS ¦ Gregory Wu, PhD
   • B cell Responses of Adult and Pediatric Transverse Myelitis ¦ Nancy Monson, PhD
   • Disease Modifying Therapies Reveal Inflammatory and Anti-inflammatory Functions of B-cells in MS ¦ Robert Axtell, PhD
   • Mechanisms of Action of Ocrelizumab in MS ¦ Anne Cross, MD
   • Wrap-up ¦ Anne Cross, MD
6. Neuromyelitis Optica Spectrum Disorders: Current Issues in Diagnosis and Management
   
   • Overview ¦ Brian Weinshenker, MD
   • Diagnosis
     • Limited Syndromes: Myelitis, Optic Neuritis, Single and Recurrent ¦ Dean Wingerchuk, MD, MSc, FRCP(C)
     • Brain Syndromes in NMOSD ¦ Marcelo Matiello, MD
     • Overlap of MS and NMO ¦ Anu Jacob, MD
     • NMO “Mimics” ¦ Anu Jacob, MD
     • Comorbidities: Autoimmunity (non-CNS, CNS) ¦ Brian Weinshenker, MD
     • Paraneoplastic NMOSD ¦ Marcelo Matiello, MD
   • Serologic Diagnosis
     • False Positive ¦ Marcelo Matiello, MD
     • False Negative (including MOG) ¦ Anu Jacob, MD
   • Management
     • Relapse Management: Consensus and Controversies ¦ Marcelo Matiello, MD
     • Indication for and Initial Treatment Choices for Long Term Therapy: Consensus and Controversies ¦ Anu Jacob, MD
     • Aggressive Disease/Treatment Failure ¦ Dean Wingerchuk, MD, MSc, FRCP(C)
     • Pregnancy ¦ Brian Weinshenker, MD
     • Onset in Pregnancy/Relapse in Pregnancy
     • Maintenance Treatment: Planned and “Unplanned” Pregnancy
     • Stopping Therapy ¦ Dean Wingerchuk, MD, MSc, FRCP(C)
   • Conclusion Brian Weinshenker, MD
7. The Future of MS Imaging
   • Welcome and Goals: Presenting the NAIMS Cooperative ¦ Daniel S. Reich, MD, PhD
   • Role of Advancing Imaging in Diagnosing (and Not Misdiagnosing) MS ¦ Andrew Solomon, MD
   • Stretch ¦ Daniel Reich, MD, PhD
   • Role of Advanced Imaging in Predicting and Tracking MS Course ¦ Jiwon Oh, MD, PhD, FRCPC
   • Role of Advanced Imaging in Unraveling MS Pathophysiology ¦ Pascal Sati, PhD
   • Discussion and Wrap-up
8. John Whitaker Memorial Lecture: Therapeutic Exploitation of Crosstalk Between the Immune and Nervous SystemsFrauke Zipp, MD
9. Whitaker Track Invited Lectures
   • Welcome and Introduction ¦ Michael K. Racke, MD
   • The Role of Stress Granules and RNA Binding Protein Dysfunction in the Pathogenesis of Neurodegeneration in MS ¦ Michael Levin, MD, FRCPC, FAAN, FANA
   • Serum Neurofilament Light Chain: The Neurologist‘s C-reactive Protein? Can We Rely on Serum NfL in the Future? ¦ Jens Kuhle, MD, PhD
   • Disability-specific and Sex-specific Approach to Neuroprotection in MS ¦ Rhonda Voskuhl, MD
   • Q&A, Closing ¦ Michael K. Racke, MD
10. Genetic Risk
    • Introduction and Objectives ¦ Sergio E. Baranzini, PhD
    • Genetic Susceptibility in MS ¦ Stephen Sawcer, MD, PhD
    • From Genes to Pathways: How Common Variants in DNA Can Result in MS Risk ¦ Sergio E. Baranzini, PhD
    • The Role of Rare DNA Variants in MS Susceptibility ¦ Chris Cotsapas, PhD
    • MS Genetics in Non-Europeans ¦ Jacob McCauley, PhD
11. Basic Immunology for the Non-immunologist
    • How Does the Immune System Protect Us? ¦ Lisa Fox, PA
    • What Causes CNS Inflammation in MS? ¦ Scott D. Newsome, DO, MSCN, FAAN
    • How Do the Current DMTs Affect the Altered Immune Response in MS? ¦ Scott D. Newsome, DO, MSCN, FAAN
12. Advanced Immunology for the Non-immunologist
    • The Innate Immune System: An Emerging Target in MS ¦ Michael Kornberg, MD, PhD
    • The Innate Immune System: Effect of MS Disease Modifying Therapies ¦ Robert J. Fox, MD
    • Q&A

Nursing

1. Challenges and Considerations with Infusible TherapiesAll Presentations
   • Introduction ¦ Colleen Harris, MN, NP, MSCN, MSCS; Denise Bruen, MSN, APRN-BC, MSCN
   • Pre-infusion Preparation ¦ Colleen Harris, MN, NP, MSCN, MSCS
   • Infusions and Maintenance of Therapies ¦ Denise Bruen, MSN, APRN-BC, MSCN
   • Case Studies ¦ Colleen Harris, MN, NP, MSCN, MSCS; Denise Bruen, MSN, APRN-BC, MSCN
2. Treatment Adherence in MS: Identifying Suboptimal Adherence and Strategies for Improving Appointment Attendance and Medication Self-Management
   • Introduction ¦ Jodie K. Haselkorn, MD, MPH
   • Using Clinical Data to Build Predictive and Explanatory Models of Treatment Adherence ¦ Elizabeth S. Gromisch, PhD
   • Psychological Considerations in Suboptimal DMT Adherence ¦ Aaron Turner, PhD, ABPP
   • Using Motivational Interviewing and Telehealth to Improve Adherence ¦ Aaron Turner, PhD, ABPP; Alicia Sloan, MPH, MSW
   • Implementing Strategies into a Clinical Setting ¦ Panel
3. Update on Communication Skills: Using New Tools in Conversations with Patients
   • Course Overview ¦ Marie Namey, APRN, MSCN
   • Communication: The CPR of Healthcare ¦ E. Mary Johnson, RN, BSN, NE-BC
   • Shared Decision Making: Patient Centered Health Care ¦ Marie Namey, APRN, MSCN; Ellen Reardon, RN, MSN
   • Panel Discussion ¦ Panel

Psychosocial: Cognition, Depression

1. Managing Fatigue and Sleep Disorders in People with MSAll Presentations
   • Invisible Symptoms: Prevalence Statistics of Fatigue and Sleep Disorders in MS ¦ Amy Sullivan, PsyD, ABPP
   • Modifying Empirically Validated Sleep Interventions for the MS Population ¦  Michelle Drerup, PsyD, DBSM
   • Research and Outcome Data on Treatment of Insomnia in the MS Population ¦  Catherine Siengsukon, PT, PhD
   • Ask the Experts ¦ Panel
2. Whitaker Platform Presentations
   
   • Welcome and Introduction ¦ Michael Racke, MD
   • A Model for Examining Novel Mechanisms of Neurodegeneration in an Animal Model of Multiple Sclerosis ¦ Cole Libner, BSc
   • Does 4 Weeks of Cognitive Rehabilitation Improve Processing Speed and Working Memory in MS? Results of Mindfulness Training Vs. Adaptive Computerized Training ¦ Heena Manglani, MA
   • Dysfunctional RNA Binding Protein Biology as Contributors to the Pathogenesis of Autoimmune Disease of the Central Nervous System ¦ Hannah Salapa, BS
   • Interferon Signature and Regulation in Progressive Multiple Sclerosis: Effects of Sc IFN-Beta-1a ¦ Xuan Feng, PhD
   • Q&A, Closing ¦ Michael Racke, MD
3. Psychopharmacology and MS: Review and Update for Clinicians
   
   • Psychopharmacology Overview: Classification, Indications, Mechanism of Action, and Common Adverse Effects of Psychopharmacological Agents ¦ Jane Erb, MD
   • Use of Psychotropics in MS: Antidepressants, Antianxiety Agents, Mood Stabilizers, Antipsychotics, Cognitive Enhancers, and Cannabis  ¦ Laura Safar, MD
   • Psychotropics Algorithm Selection Based on Clinical Scenario – Clinical Vignettes Discussion with Audience Participation  ¦ Panel
4. Utilizing the Power of the Arts in MS Care: Everyone BenefitsAll Presentations
   • Introduction ¦ Francois Bethoux, MD
   • Medical Humanities through Arts in MS – Reflective Writing and Visual Arts  ¦ Ahmed Obeidat, MD, PhD
   • Use of Therapeutic Arts in an MS Clinic  ¦ Lisa Gallagher, MA, MT-BC
   • Evidence Supporting the Use of the Arts in the Management of MS  ¦ Francois Bethoux, MD
   • Musical Experience  ¦ Lisa Gallagher, MA, MT-BC
5. Affective Disorders and Personality Changes in MS
   • Introduction ¦ Frederick W. Foley, PhD
   • Epidemiology of Affective Disorders in MS: What We Know and What Gaps there are in Knowledge ¦ Scott B. Patten, MD
   • MRI Correlates and Pharmacological Treatment of Affective Disorders in MS ¦ Anthony Feinstein, MD, PhD
   • Personality Traits in Relation to Cognitive Impairment and Brain MRI in MS ¦ Ralph H B Benedict, PhD, ABPP-CN
6. Fundamentals of Multiple Sclerosis Care 2019: Identifying the Disease and Managing the Course (Part 2)
   • RRMS: Current Treatment Options, Considerations in Choosing Treatment, Acute Relapse Management ¦ John Rinker, MD
   • Identifying and Managing Mood Disorders in MS ¦ Anthony Feinstein, MD, PhD
   • Women’s Issues in MS: Pregnancy, Menopause, Sexual Function ¦ Mitzi Joi Williams, MD
   • Integrative Medicine in the Comprehensive Care Model of MS ¦ Megan Weigel, DNP, ARNP-C, MSCN
7. Supporting and Caring For Each Other While Living with MS: The Support Partners’ PerspectiveAll Presentations
   • Introductions and Orientation to Session ¦ Deborah Miller, PhD, LISW
   • Presentation and Discussion of Vignette 1: Teen with MS and Mother ¦ Rosalind Kalb, PhD
   • Presentation and Discussion of Vignette 2: Newly Diagnosed Couple ¦ Matthew Sacco, PhD
   • Presentation and Discussion of Vignette 3: Older Couple ¦ Lucille Carriere, PhD
8. Mental Health Care Delivery Models for Patients with MS
   • The Current Landscape: Individuals with MS Need Better Access to Mental Health Services ¦ Sarah Minden, MD
   • Collaborative Care Model in Mental Health: Description, Components, and Review of its Evidence ¦ Jane Erb, MD
   • The Neurologist Perspective – Mental Health Needs of MS Patients and Role of the Neurologist ¦ Maria K. Houtchens, MD, MMsci
   • Q&A
   • Can the Collaborative Care Model Address the Mental Health Needs of Individuals with MS? Challenges and Opportunities ¦ Laura T. Safar, MD
   • The Social Worker Perspective – Care Management for MS Patients: Current Models and Future Developments ¦ Elizabeth Misasi, LICSW
   • Panel Discussion – Professional Adaptation and Role Changes in New Models ¦ Panel
   • Q&A ¦ Panel
9. Managing the Suicidal Patient in Your Clinic: Red Flags, Ethical Considerations & Emotional AftermathAll Presentations
   • What We Know about Depression and Suicide in MS and their Impact on Individuals and their Families ¦ Rosalind Kalb, PhD
   • Before & After: Recognizing Red Flags, Dealing with the Aftermath ¦ Mary Alissa Willis, MD
   • Managing the Suicidal Patient in a Private Practice Setting: Legal and Ethical Considerations ¦ Amanda Rohrig, PT; Lauren R. Sankary, JD, MA
   • Interdisciplinary Discussion of Suicide-related Challenges ¦ Panel
10. Platform Presentations: Psychosocial: Cognition, Depression
    • PSY01: Cognition Following Mesenchymal Stem Cell Therapy in Multiple Sclerosis: An Interim Analysis ¦ Lisa Walker, PhD
    • PSY02: Contributions of the Rey Auditory Verbal Learning Test to Cognitive Impairment on the Brief International Cognitive Assessment for Multiple Sclerosis ¦ Abbey Hughes, PhD
    • PSY03: Neurobehavioral Correlates of Hazardous Cannabis Use in Multiple Sclerosis ¦ Abbey Hughes, PhD
    • PSY04: Using Connectome-Based Predictive Modeling to Derive Neuromarkers of Cognition in MS ¦ Ruchika Prakash, PhD
    • PSY05: Correlates of Cognitive Performance and Perceived Cognitive Abilities Among Hispanic and Black Individuals with Multiple Sclerosis ¦ Alexa Stuifbergen, RN, PhD, FAAN
    • PSY06: How Anxiety and Fatigue Interact to Interfere with Processing Speed in MS ¦ Caroline Altaras, MA
11. Case Studies in Cognition in MSJeffrey Wilken, PhD; Lori Ann Kostich, MS, CCC-SLP
12. Treatment Adherence in MS: Identifying Suboptimal Adherence and Strategies for Improving Appointment Attendance and Medication Self-Management
    • Introduction ¦ Jodie K. Haselkorn, MD, MPH
    • Using Clinical Data to Build Predictive and Explanatory Models of Treatment Adherence ¦ Elizabeth S. Gromisch, PhD
    • Psychological Considerations in Suboptimal DMT Adherence ¦ Aaron Turner, PhD, ABPP
    • Using Motivational Interviewing and Telehealth to Improve Adherence ¦ Aaron Turner, PhD, ABPP; Alicia Sloan, MPH, MSW
    • Implementing Strategies into a Clinical Setting ¦ Panel
13. Sex and MS: How to Help Patients with MS Who Experience Sexual DysfunctionKimberly Castelo, MS, LMFT, CST

Rehabilitation

1. Current Topics and Trends in MS Rehabilitation (Part 1)
   • Neuromodulation in MS ¦ Hesham Abboud, MD, PhD
   • Neuromuscular and Cardiovascular Considerations for Exercise in MS ¦ Alexander Ng, PhD, FACSM
2. Current Topics and Trends in MS Rehabilitation (Part 2)
   • MS Rehab Research: Turning a Burning Clinical Question into a Research Project  ¦ Donna Fry, PT, PhD; Herb Karpatkin, PT, DSc, NCS, MSCS; Lori Ann Kostich, MS, CCC-SLP, MSCS
3. Current Topics and Trends in MS Rehabilitation (Part 3)
   • Occupational Therapy Assessment and Intervention in Multiple Sclerosis: A Behavior-based Approach ¦ Shaina Meyer, OTR/L, MSCS; Rebecca Cunningham, OTD, OTR/L
   • Computer Based Rehab Outcome Measures: The Future is Now ¦ Matt Sutliff, PT, DPT, MSC
4. Platform Presentations: Rehabilitation
   • RHI01: Environmental Correlates of Physical Activity in Persons with Multiple Sclerosis ¦ Stephanie Silveira, PhD
   • RHI02: Physical Activity and Walking Performance across the Lifespan in Multiple Sclerosis ¦ Jessica Baird, PhD
   • RHI03: Physical and Cognitive Fatigue across the Lifespan in Persons with Multiple Sclerosis ¦ Catherine Jones, MSPH
   • RHI04: Psychometric Comparisons of Computer-Adaptive Test and Standard Balance and Walking Scales to Assess Functional Mobility in People with MS ¦ Hina Garg, PT, MS, PhD, NCS
   • RHI05: Persons with Multiple Sclerosis with Severe Disability Exhibit Muscular Strength Asymmetries in Both Upper and Lower Extremities ¦ John Farrell III, PhD
   • RHI06: Manual Dexterity and Computerized Cognitive Testing in People with Multiple Sclerosis: Motor Domain Reflects More Than Just What Is in the Hand ¦ Jared Srinivasan, BA
5. New Developments in MS Rehabilitation and Telerehabilitation (VA MSCoE)All Presentations
   • Introduction ¦ Jodie Haselkorn, MD, MPH
   • Overview of Existing Telerehabilitation in MS in Current Practice ¦ Mitchell T. Wallin, MD, MPH
   • Novel Applications of Telerehabilitation Technology ¦ Shane Chanpimol, PT, DPT
   • Strategies to Enhance Function in MS through Rehabilitation Intensity, Duration and Timing ¦ Jodie Haselkorn, MD, MPH
   • Current Evidence-based Rehabilitation Interventions for Fall Prevention in MS ¦ Michele Cameron, MD, PT, MCR
   • Discussion ¦ Panel

Research

1. Opening Lecture: Mountains to Climb: The Cause, Treatment and Care of MS in the Pacific NorthwestJames Bowen, MD
2. Clinical Trials and Technology: What We Know, What is Coming?
   • Responsibilities of the Investigator: Current Use of Electronic Data Capture ¦ Andrew Goodman, MD, FAAN, FANA
   • Research Technology in the Clinic: A Learning Health Care System ¦ Kelsey Yoo, PA
   • Telemedicine Techniques in Clinical Research: Current and Future Use ¦ Lee Gerwitz, MD
   • Q&A ¦ Andrew Goodman, MD, FAAN, FANA
3. The Evolving Research Landscape: Understanding, Designing, and Analyzing Studies in Multiple SclerosisAll Presentations
   • Introduction to Clinical Research: When, Why, and How ¦  Kavita Nair, PhD
   • Understanding and Interpreting Clinical Trial Design in Multiple Sclerosis ¦  Enrique Alvarez, MD, PhD
   • Real World Observational Studies in Multiple Sclerosis ¦  Carrie Hersh, DO, MSc
   • Q&A ¦  Panel
4. Current Topics and Trends in MS Rehabilitation (Part 2)
   • MS Rehab Research: Turning a Burning Clinical Question into a Research Project  ¦  Donna Fry, PT, PhD; Herb Karpatkin, PT, DSc, NCS, MSCS; Lori Ann Kostich, MS, CCC-SLP, MSCS

Skills Development

1. Interventions for Success at Work: Research to Application
   • Research Pertaining to Employment and MS ¦ Ralph H B Benedict, PhD, ABPP-CN
   • Medical Management Supporting the Employed Individual ¦ Amy Neal, MS PA-C
   • Supports Provided by Rehabilitation ¦ Lori Ann Kostich, MS, CCC-SLP, MSCS
   • Accommodations to Help Manage the Work Environment ¦ Shaheen Virani, MA, CRC
2. Challenges and Considerations with Infusible TherapiesAll Presentations
   • Introduction ¦ Colleen Harris, MN, NP, MSCN, MSCS; Denise Bruen, MSN, APRN-BC, MSCN
   • Pre-infusion Preparation ¦ Colleen Harris, MN, NP, MSCN, MSCS
   • Infusions and Maintenance of Therapies ¦ Denise Bruen, MSN, APRN-BC, MSCN
   • Case Studies ¦ Colleen Harris, MN, NP, MSCN, MSCS; Denise Bruen, MSN, APRN-BC, MSCN
3. Update on Communication Skills: Using New Tools in Conversations with Patients
   • Course Overview ¦ Marie Namey, APRN, MSCN
   • Communication: The CPR of Healthcare ¦ E. Mary Johnson, RN, BSN, NE-BC
   • Shared Decision Making: Patient Centered Health Care ¦ Marie Namey, APRN, MSCN; Ellen Reardon, RN, MSN
   • Panel Discussion ¦ Panel

Symptomatic Management

1. Fibromyalgia and Myofascial Pain in MS PatientsDavid Brandes, MS, MD, FAAN, MSC
2. An MS Health Professional’s Guide to Cannabis Allen C. Bowling, MD, PhD
   • History, Botany, Pharmacology
   • Efficacy and Safety
   • Drug Interactions and Special Considerations
   • The Critical Role of MS Health Professionals
3. Multidisciplinary Management of Chronic Pain in MS
   • Introduction to Multidisciplinary Management of Chronic Pain in MS ¦ Kevin Alschuler, PhD
   • Management of the MS Patient with Chronic Pain ¦ Brett R. Stacey, MD
   • Is There a Role for Opioids in MS Pain Management? A Case-Based Discussion ¦ Pamela Stitzlein Davies, MS, ARNP, FAANP
   • Physical Activity and Chronic Pain in MS ¦ Robert W. Motl, PhD
   • Cognitive Behavioral Interventions for Chronic Pain ¦ Dawn M. Ehde, PhD
   • Q&A ¦ Panel
4. Fundamentals of Multiple Sclerosis Care 2019: Identifying the Disease and Managing the Course (Part 2)
   • RRMS: Current Treatment Options, Considerations in Choosing Treatment, Acute Relapse Management ¦ John Rinker, MD
   • Identifying and Managing Mood Disorders in MS ¦ Anthony Feinstein, MD, PhD
   • Women’s Issues in MS: Pregnancy, Menopause, Sexual Function ¦ Mitzi Joi Williams, MD
   • Integrative Medicine in the Comprehensive Care Model of MS ¦ Megan Weigel, DNP, ARNP-C, MSCN
5. Fundamentals of Multiple Sclerosis Care 2019 (Part 3)
   • Multidisciplinary Approach to Symptom Management ¦ Beverly Layton, RN, BSN, CCRC, MSCN
   • Pearls from Advanced Practice: Disease Modifying Therapies ¦ Marie Moore, MSN, FNP, MSCN
   • Emerging Role of Pharmacists in MS Centers ¦ Brittany Denson, PharmD
   • Current Options in Comprehensive Fatigue Management ¦ Patricia Pagnotta, ANP-C, MSCN
   • Symptoms Below the Belt: Strategies in the Management of Elimination and Sexual Dysfunction ¦ Marie Namey, APRN, MSN, MSCN
6. Complex Symptoms in MS: Assessment and Management Strategies
   • Welcome and Overview ¦ Kathleen Costello, MS, ANP-BC, MSCN
   • Balance Issues in MS ¦ Jeffrey Hebert, PhD, PT
   • Spasticity and MS ¦ Susan Bennett, PT, DPT, EdD, NCS, MSCS
   • Visual Disturbances ¦ Robert K. Shin, MD
   • Q&A ¦ Panel
7. Mental Health Care Delivery Models for Patients with MS
   • The Current Landscape: Individuals with MS Need Better Access to Mental Health Services ¦ Sarah Minden, MD
   • Collaborative Care Model in Mental Health: Description, Components, and Review of its Evidence ¦ Jane Erb, MD
   • The Neurologist Perspective – Mental Health Needs of MS Patients and Role of the Neurologist ¦ Maria K. Houtchens, MD, MMsci
   • Q&A
   • Can the Collaborative Care Model Address the Mental Health Needs of Individuals with MS? Challenges and Opportunities ¦ Laura T. Safar, MD
   • The Social Worker Perspective – Care Management for MS Patients: Current Models and Future Developments ¦ Elizabeth Misasi, LICSW
   • Panel Discussion – Professional Adaptation and Role Changes in New Models ¦ Panel
   • Q&A ¦ Panel
8. Platform Presentations: Disease Assessment and Management
   • DXA01 Inroads: A Phase 3 Study to Assess the Efficacy and Safety of ADS-5102 (Amantadine) Extended Release Capsules in Multiple Sclerosis (MS) Patients with Walking Impairment ¦ Michelle Cameron, MD, PT, MCR
   • DXA02 Sleep Quality and Physical Activity in Youth with Multiple Sclerosis ¦ Stephanie Grover, MSc, CCRP
   • DXA03 Relevance of Timing of Mog Serum Testing: Does Positivity Always Signal Recurrence? ¦ Giulia Longoni, MD
   • DXA04 Impact of Cognitive Behavioral Therapy for Insomnia or Brief Sleep Education on Insomnia Symptoms, Fatigue, Depression, and Anxiety in Individuals with Multiple Sclerosis ¦ Stacy Coffyn, SPT
   • DXA05 Physical Activity, Sedentary Behavior, and Sleep Quality in Adults with Multiple Sclerosis across the Lifespan ¦ Katie Cederberg, MS
   • DXA06 The Economic Impact of Multiple Sclerosis: A Preliminary Look at the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) (on behalf of the NARCRMS HEOR Advisory Group) ¦ Kottil Rammohan, MD
9. Beyond the PI: Drug-Drug Interactions (DDIs), Monitoring and Management
   • Precision Medicine and Applied Pharmacology for Anti-Depressants, Anti-Psychotics to Assist in Drug Selection and Monitoring to Avert Comorbidities in Patients with MS ¦ Rebecca Barnhart, PharmD, BCPP
   • Anatomy of Pharmacokinetic/ Pharmacodynamic Drug Interaction Implications ¦ Felecia Hart, PharmD, MSCS

Technological Advances

1. Whitaker Platform Presentations
   
   • Welcome and Introduction ¦ Michael Racke, MD
   • A Model for Examining Novel Mechanisms of Neurodegeneration in an Animal Model of Multiple Sclerosis ¦ Cole Libner, BSc
   • Does 4 Weeks of Cognitive Rehabilitation Improve Processing Speed and Working Memory in MS? Results of Mindfulness Training Vs. Adaptive Computerized Training ¦ Heena Manglani, MA
   • Dysfunctional RNA Binding Protein Biology as Contributors to the Pathogenesis of Autoimmune Disease of the Central Nervous System ¦ Hannah Salapa, BS
   • Interferon Signature and Regulation in Progressive Multiple Sclerosis: Effects of Sc IFN-Beta-1a ¦ Xuan Feng, PhD
   • Q&A, Closing ¦ Michael Racke, MD
2. Clinical Trials and Technology: What We Know, What is Coming?
   • Responsibilities of the Investigator: Current Use of Electronic Data Capture ¦ Andrew Goodman, MD, FAAN, FANA
   • Research Technology in the Clinic: A Learning Health Care System ¦ Kelsey Yoo, PA
   • Telemedicine Techniques in Clinical Research: Current and Future Use ¦ Lee Gerwitz, MD
   • Q&A ¦ Andrew Goodman, MD, FAAN, FANA
3. The Future of MS Imaging
   • Welcome and Goals: Presenting the NAIMS Cooperative ¦ Daniel S. Reich, MD, PhD
   • Role of Advancing Imaging in Diagnosing (and Not Misdiagnosing) MS ¦ Andrew Solomon, MD
   • Stretch ¦ Daniel Reich, MD, PhD
   • Role of Advanced Imaging in Predicting and Tracking MS Course ¦ Jiwon Oh, MD, PhD, FRCPC
   • Role of Advanced Imaging in Unraveling MS Pathophysiology ¦ Pascal Sati, PhD
   • Discussion and Wrap-up
4. Current Topics and Trends in MS Rehabilitation (Part 3)
   • Occupational Therapy Assessment and Intervention in Multiple Sclerosis: A Behavior-based Approach ¦ Shaina Meyer, OTR/L, MSCS; Rebecca Cunningham, OTD, OTR/L
   • Computer Based Rehab Outcome Measures: The Future is Now ¦ Matt Sutliff, PT, DPT, MSC
5. New Technology in MS
   • The Brave New World of Technology ¦ Gabriel Pardo, MD, FAAN
   • Digital Innovations; Reshaping How We See MS ¦ Daniel Pelletier, MD
   • New Approaches to Solving Old Problems ¦ Darin Okuda, MD
   • Q&A ¦ Panel
6. New Developments in MS Rehabilitation and Telerehabilitation (VA MSCoE)All Presentations
   • Introduction ¦ Jodie Haselkorn, MD, MPH
   • Overview of Existing Telerehabilitation in MS in Current Practice ¦ Mitchell T. Wallin, MD, MPH
   • Novel Applications of Telerehabilitation Technology ¦ Shane Chanpimol, PT, DPT
   • Strategies to Enhance Function in MS through Rehabilitation Intensity, Duration and Timing ¦ Jodie Haselkorn, MD, MPH
   • Current Evidence-based Rehabilitation Interventions for Fall Prevention in MS ¦ Michele Cameron, MD, PT, MCR
   • Discussion ¦ Panel

Wellness

1. Improving the Health and Wellness of People with Advanced MS through Community Partnerships
   • Creating Partnerships for Healthier Outcomes ¦ Rachael Stacom, MS, ANP-BC, MSCN
   • Building an Effective Peer Support/Mentoring Program for People Living with Multiple Sclerosis ¦ Elaine Castelluccio, PT, MPT, MSCS
   • Being a Peer Mentor: The Lived Experience ¦ Cathy Kiler-McFadden
2. The Importance of Community Based Programs to Enhance Comprehensive MS Care
   • Welcome and Introduction of Speakers ¦ Brian Hutchinson, PT, MSCS
   • Community-Based Wellness Models for Chronic Disease ¦ Brian Hutchinson, PT, MSCS
   • Building MS Communities, Expanding the Continuum of Care ¦ James Bowen, MD
   • A Community Based Yoga Program for People with MS: The Power of Connection ¦ Megan Weigel, DNP, ARNP-c, MSCN
   • The Multiple Sclerosis Achievement Center: A Day Program Model for People with MS ¦ Brian Hutchinson, PT, MSCS
3. Fundamentals of Multiple Sclerosis Care 2019: Identifying the Disease and Managing the Course (Part 2)
   • RRMS: Current Treatment Options, Considerations in Choosing Treatment, Acute Relapse Management ¦ John Rinker, MD
   • Identifying and Managing Mood Disorders in MS ¦ Anthony Feinstein, MD, PhD
   • Women’s Issues in MS: Pregnancy, Menopause, Sexual Function ¦ Mitzi Joi Williams, MD
   • Integrative Medicine in the Comprehensive Care Model of MS ¦ Megan Weigel, DNP, ARNP-C, MSCN
4. Integrative Medicine: An Essential But Neglected Component of Comprehensive MS Care
   • Introduction, Relevance to Comprehensive Care, Science and Clinical Application, Research Update ¦ Allen C. Bowling, MD, PhD
   • Calorie-Restriction and Other Dietary Modification Strategies for MS Course ¦ Kathryn Fitzgerald, ScD, ScM
   • Constraint-Induced Movement Therapy ¦ Victor Mark, MD
   • Can High Intensity Training in MS Further Optimize Exercise Therapy Outcome? ¦ Charly Keytsman, PhD
5. Leveraging Multidisciplinary Care to Enhance Wellness in Individuals with MS
   • Leveraging Multidisciplinary Care to Enhance Wellness in Individuals with MS ¦ Gloria von Geldern, MD
   • Encouraging Wellness Behaviors and Integrating Wellness into Neurologic Care ¦ Annette Wundes, MD
   • Guiding Patients through the Complex World of MS Care ¦ Debra Cramer, RN
   • Physiatry and Rehabilitation Therapy Interventions to Promote Wellness ¦ Gloria Hou, MD
   • Promoting Wellness through Education, Employment, and Volunteering ¦ Joe Stuckey, MS, CRC
   • Promoting Wellness Behaviors through Health Behavior Change Interventions ¦ Samantha Artherholt, PhD